Wortmannin

Identification

Name
Wortmannin
Accession Number
DB08059
Type
Small Molecule
Groups
Experimental
Description

Wortmannin, a steroid metabolite of the fungi Penicillium funiculosum, Talaromyces wortmannii, is a non-specific, covalent inhibitor of phosphoinositide 3-kinases (PI3Ks).

Structure
Thumb
Synonyms
  • Wartmannin
External IDs
NSC-627609 / SL-2052
Categories
UNII
XVA4O219QW
CAS number
19545-26-7
Weight
Average: 428.4319
Monoisotopic: 428.147117744
Chemical Formula
C23H24O8
InChI Key
QDLHCMPXEPAAMD-QAIWCSMKSA-N
InChI
InChI=1S/C23H24O8/c1-10(24)30-13-7-22(2)12(5-6-14(22)25)16-18(13)23(3)15(9-28-4)31-21(27)11-8-29-20(17(11)23)19(16)26/h8,12-13,15H,5-7,9H2,1-4H3/t12-,13+,15+,22-,23-/m0/s1
IUPAC Name
(1R,3R,5S,9R,18S)-18-(methoxymethyl)-1,5-dimethyl-6,11,16-trioxo-13,17-dioxapentacyclo[10.6.1.0^{2,10}.0^{5,9}.0^{15,19}]nonadeca-2(10),12(19),14-trien-3-yl acetate
SMILES
[H][C@@]12CCC(=O)[C@@]1(C)C[C@@H](OC(C)=O)C1=C2C(=O)C2=C3C(=CO2)C(=O)O[C@H](COC)[C@]13C

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
UPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoformNot AvailableHuman
USerine/threonine-protein kinase PLK1Not AvailableHuman
UPhosphatidylinositol 3-kinase regulatory subunit alphaNot AvailableHuman
UPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformNot AvailableHuman
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AgmatineThe therapeutic efficacy of Wortmannin can be increased when used in combination with Agmatine.Experimental, Investigational
AmiodaroneThe therapeutic efficacy of Wortmannin can be increased when used in combination with Amiodarone.Approved, Investigational
AmlodipineThe therapeutic efficacy of Wortmannin can be increased when used in combination with Amlodipine.Approved
Amphotericin BThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Wortmannin.Approved, Investigational
AmrinoneThe therapeutic efficacy of Wortmannin can be increased when used in combination with Amrinone.Approved
Anthrax immune globulin humanThe risk or severity of adverse effects can be increased when Wortmannin is combined with Anthrax immune globulin human.Approved
AranidipineThe therapeutic efficacy of Wortmannin can be increased when used in combination with Aranidipine.Approved, Investigational
AzelnidipineThe therapeutic efficacy of Wortmannin can be increased when used in combination with Azelnidipine.Approved, Investigational
AzimilideThe therapeutic efficacy of Wortmannin can be increased when used in combination with Azimilide.Investigational
Bacillus calmette-guerin substrain connaught live antigenThe risk or severity of adverse effects can be increased when Wortmannin is combined with Bacillus calmette-guerin substrain connaught live antigen.Approved, Investigational
Bacillus calmette-guerin substrain tice live antigenThe risk or severity of adverse effects can be increased when Wortmannin is combined with Bacillus calmette-guerin substrain tice live antigen.Approved
BarnidipineThe therapeutic efficacy of Wortmannin can be increased when used in combination with Barnidipine.Approved
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Wortmannin.Investigational
BencyclaneThe therapeutic efficacy of Wortmannin can be increased when used in combination with Bencyclane.Experimental
BenidipineThe therapeutic efficacy of Wortmannin can be increased when used in combination with Benidipine.Approved, Investigational
BepridilThe therapeutic efficacy of Wortmannin can be increased when used in combination with Bepridil.Approved, Withdrawn
BioallethrinThe therapeutic efficacy of Wortmannin can be increased when used in combination with Bioallethrin.Approved, Experimental
BuspironeThe metabolism of Buspirone can be decreased when combined with Wortmannin.Approved, Investigational
BusulfanThe serum concentration of Busulfan can be increased when it is combined with Wortmannin.Approved, Investigational
CarboxyamidotriazoleThe therapeutic efficacy of Wortmannin can be increased when used in combination with Carboxyamidotriazole.Investigational
CaroverineThe therapeutic efficacy of Wortmannin can be increased when used in combination with Caroverine.Experimental
CilnidipineThe therapeutic efficacy of Wortmannin can be increased when used in combination with Cilnidipine.Approved, Investigational
CinnarizineThe therapeutic efficacy of Wortmannin can be increased when used in combination with Cinnarizine.Approved, Investigational
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Wortmannin.Approved, Investigational, Withdrawn
ClevidipineThe therapeutic efficacy of Wortmannin can be increased when used in combination with Clevidipine.Approved, Investigational
Clostridium tetani toxoid antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Wortmannin is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Wortmannin is combined with Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated).Approved
CyclandelateThe therapeutic efficacy of Wortmannin can be increased when used in combination with Cyclandelate.Approved
CyclosporineThe metabolism of Cyclosporine can be decreased when combined with Wortmannin.Approved, Investigational, Vet Approved
DarodipineThe therapeutic efficacy of Wortmannin can be increased when used in combination with Darodipine.Experimental
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Wortmannin.Approved
DidanosineDidanosine can cause a decrease in the absorption of Wortmannin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DiltiazemThe therapeutic efficacy of Wortmannin can be increased when used in combination with Diltiazem.Approved, Investigational
DocetaxelThe metabolism of Docetaxel can be decreased when combined with Wortmannin.Approved, Investigational
DofetilideThe serum concentration of Dofetilide can be increased when it is combined with Wortmannin.Approved, Investigational
DotarizineThe therapeutic efficacy of Wortmannin can be increased when used in combination with Dotarizine.Investigational
EfonidipineThe therapeutic efficacy of Wortmannin can be increased when used in combination with Efonidipine.Approved, Investigational
EperisoneThe therapeutic efficacy of Wortmannin can be increased when used in combination with Eperisone.Approved, Investigational
EthosuximideThe therapeutic efficacy of Wortmannin can be increased when used in combination with Ethosuximide.Approved
EtravirineThe serum concentration of Etravirine can be increased when it is combined with Wortmannin.Approved
FelodipineThe therapeutic efficacy of Wortmannin can be increased when used in combination with Felodipine.Approved, Investigational
FendilineThe therapeutic efficacy of Wortmannin can be increased when used in combination with Fendiline.Withdrawn
FingolimodWortmannin may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
Fish oilThe therapeutic efficacy of Wortmannin can be increased when used in combination with Fish oil.Approved, Nutraceutical
FlunarizineThe therapeutic efficacy of Wortmannin can be increased when used in combination with Flunarizine.Approved
FluspirileneThe therapeutic efficacy of Wortmannin can be increased when used in combination with Fluspirilene.Approved, Investigational
FosphenytoinThe serum concentration of Wortmannin can be decreased when it is combined with Fosphenytoin.Approved, Investigational
G17DTThe risk or severity of adverse effects can be increased when Wortmannin is combined with G17DT.Investigational
GabapentinThe therapeutic efficacy of Wortmannin can be increased when used in combination with Gabapentin.Approved, Investigational
GallopamilThe therapeutic efficacy of Wortmannin can be increased when used in combination with Gallopamil.Investigational
GI-5005The risk or severity of adverse effects can be increased when Wortmannin is combined with GI-5005.Investigational
Hepatitis A VaccineThe risk or severity of adverse effects can be increased when Wortmannin is combined with Hepatitis A Vaccine.Approved
Hepatitis B Vaccine (Recombinant)The risk or severity of adverse effects can be increased when Wortmannin is combined with Hepatitis B Vaccine (Recombinant).Approved, Withdrawn
Human rabies virus immune globulinThe risk or severity of adverse effects can be increased when Wortmannin is combined with Human rabies virus immune globulin.Approved
INGN 201The risk or severity of adverse effects can be increased when Wortmannin is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Wortmannin is combined with INGN 225.Investigational
IsradipineThe therapeutic efficacy of Wortmannin can be increased when used in combination with Isradipine.Approved, Investigational
Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Wortmannin is combined with Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated).Approved
LacidipineThe therapeutic efficacy of Wortmannin can be increased when used in combination with Lacidipine.Approved, Investigational
LamotrigineThe therapeutic efficacy of Wortmannin can be increased when used in combination with Lamotrigine.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Wortmannin is combined with Leflunomide.Approved, Investigational
LercanidipineThe therapeutic efficacy of Wortmannin can be increased when used in combination with Lercanidipine.Approved, Investigational
LevetiracetamThe therapeutic efficacy of Wortmannin can be increased when used in combination with Levetiracetam.Approved, Investigational
LidoflazineThe therapeutic efficacy of Wortmannin can be increased when used in combination with Lidoflazine.Experimental
LoperamideThe therapeutic efficacy of Wortmannin can be increased when used in combination with Loperamide.Approved
LosartanThe metabolism of Losartan can be decreased when combined with Wortmannin.Approved
Magnesium sulfateThe therapeutic efficacy of Wortmannin can be increased when used in combination with Magnesium sulfate.Approved, Investigational, Vet Approved
ManidipineThe therapeutic efficacy of Wortmannin can be increased when used in combination with Manidipine.Approved, Investigational
MentholThe therapeutic efficacy of Wortmannin can be increased when used in combination with Menthol.Approved
MethsuximideThe therapeutic efficacy of Wortmannin can be increased when used in combination with Methsuximide.Approved
MibefradilThe therapeutic efficacy of Wortmannin can be increased when used in combination with Mibefradil.Investigational, Withdrawn
NaftopidilThe therapeutic efficacy of Wortmannin can be increased when used in combination with Naftopidil.Investigational
NatalizumabThe risk or severity of adverse effects can be increased when Wortmannin is combined with Natalizumab.Approved, Investigational
NicardipineThe therapeutic efficacy of Wortmannin can be increased when used in combination with Nicardipine.Approved, Investigational
NifedipineThe therapeutic efficacy of Wortmannin can be increased when used in combination with Nifedipine.Approved
NiguldipineThe therapeutic efficacy of Wortmannin can be increased when used in combination with Niguldipine.Experimental
NiludipineThe therapeutic efficacy of Wortmannin can be increased when used in combination with Niludipine.Experimental
NilvadipineThe therapeutic efficacy of Wortmannin can be increased when used in combination with Nilvadipine.Approved, Investigational
NimesulideThe therapeutic efficacy of Wortmannin can be increased when used in combination with Nimesulide.Approved, Investigational, Withdrawn
NimodipineThe therapeutic efficacy of Wortmannin can be increased when used in combination with Nimodipine.Approved, Investigational
NisoldipineThe therapeutic efficacy of Wortmannin can be increased when used in combination with Nisoldipine.Approved
NitrendipineThe therapeutic efficacy of Wortmannin can be increased when used in combination with Nitrendipine.Approved, Investigational
NylidrinThe therapeutic efficacy of Wortmannin can be increased when used in combination with Nylidrin.Approved
OcrelizumabOcrelizumab may increase the immunosuppressive activities of Wortmannin.Approved, Investigational
OtiloniumThe therapeutic efficacy of Wortmannin can be increased when used in combination with Otilonium.Experimental, Investigational
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Wortmannin.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Wortmannin.Approved, Investigational
PinaveriumThe therapeutic efficacy of Wortmannin can be increased when used in combination with Pinaverium.Approved
PrenylamineThe therapeutic efficacy of Wortmannin can be increased when used in combination with Prenylamine.Withdrawn
ProgesteroneThe absorption of Progesterone can be decreased when combined with Wortmannin.Approved, Vet Approved
QuinidineThe serum concentration of Quinidine can be increased when it is combined with Wortmannin.Approved, Investigational
Rabies virus inactivated antigen, AThe risk or severity of adverse effects can be increased when Wortmannin is combined with Rabies virus inactivated antigen, A.Approved, Investigational
Rabies virus inactivated antigen, AThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Wortmannin.Approved, Investigational
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Wortmannin.Approved, Investigational
RifabutinThe serum concentration of Rifabutin can be increased when it is combined with Wortmannin.Approved, Investigational
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Wortmannin.Approved
RifapentineThe serum concentration of Rifapentine can be increased when it is combined with Wortmannin.Approved, Investigational
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Wortmannin.Approved, Investigational
RindopepimutThe risk or severity of adverse effects can be increased when Wortmannin is combined with Rindopepimut.Investigational
RoflumilastRoflumilast may increase the immunosuppressive activities of Wortmannin.Approved
Rotavirus VaccineThe risk or severity of adverse effects can be increased when Wortmannin is combined with Rotavirus Vaccine.Approved
Rubella virus vaccineThe risk or severity of adverse effects can be increased when Wortmannin is combined with Rubella virus vaccine.Approved, Investigational
Salmonella typhi ty2 vi polysaccharide antigenThe risk or severity of adverse effects can be increased when Wortmannin is combined with Salmonella typhi ty2 vi polysaccharide antigen.Approved
Salmonella typhi ty21a live antigenThe risk or severity of adverse effects can be increased when Wortmannin is combined with Salmonella typhi ty21a live antigen.Approved
SeletracetamThe therapeutic efficacy of Wortmannin can be increased when used in combination with Seletracetam.Investigational
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Wortmannin.Approved, Investigational
SolifenacinThe metabolism of Solifenacin can be decreased when combined with Wortmannin.Approved
SRP 299The risk or severity of adverse effects can be increased when Wortmannin is combined with SRP 299.Investigational
SucralfateSucralfate can cause a decrease in the absorption of Wortmannin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SunitinibThe metabolism of Sunitinib can be decreased when combined with Wortmannin.Approved, Investigational
TacrolimusTacrolimus may increase the immunosuppressive activities of Wortmannin.Approved, Investigational
TecemotideThe risk or severity of adverse effects can be increased when Wortmannin is combined with Tecemotide.Investigational
TerodilineThe therapeutic efficacy of Wortmannin can be increased when used in combination with Terodiline.Experimental
TetrahydropalmatineThe therapeutic efficacy of Wortmannin can be increased when used in combination with Tetrahydropalmatine.Investigational
TG4010The risk or severity of adverse effects can be increased when Wortmannin is combined with TG4010.Investigational
TofacitinibWortmannin may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
Tolfenamic AcidThe therapeutic efficacy of Wortmannin can be increased when used in combination with Tolfenamic Acid.Approved, Investigational
TranilastThe therapeutic efficacy of Wortmannin can be increased when used in combination with Tranilast.Approved, Investigational
TrastuzumabTrastuzumab may increase the neutropenic activities of Wortmannin.Approved, Investigational
TrimebutineThe therapeutic efficacy of Wortmannin can be increased when used in combination with Trimebutine.Approved
TrimethadioneThe therapeutic efficacy of Wortmannin can be increased when used in combination with Trimethadione.Approved
Typhoid VaccineThe risk or severity of adverse effects can be increased when Wortmannin is combined with Typhoid Vaccine.Approved
Varicella Zoster Vaccine (Live/Attenuated)The risk or severity of adverse effects can be increased when Wortmannin is combined with Varicella Zoster Vaccine (Live/Attenuated).Approved
VerapamilThe therapeutic efficacy of Wortmannin can be increased when used in combination with Verapamil.Approved
VinpocetineThe therapeutic efficacy of Wortmannin can be increased when used in combination with Vinpocetine.Investigational
WIN 55212-2The therapeutic efficacy of Wortmannin can be increased when used in combination with WIN 55212-2.Experimental
Yellow Fever VaccineThe risk or severity of adverse effects can be increased when Wortmannin is combined with Yellow Fever Vaccine.Approved, Investigational
ZiconotideThe therapeutic efficacy of Wortmannin can be increased when used in combination with Ziconotide.Approved
ZolpidemThe serum concentration of Zolpidem can be increased when it is combined with Wortmannin.Approved
ZonisamideThe therapeutic efficacy of Wortmannin can be increased when used in combination with Zonisamide.Approved, Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
KEGG Compound
C15181
PubChem Compound
312145
PubChem Substance
99444530
ChemSpider
276037
BindingDB
15234
ChEBI
52289
ChEMBL
CHEMBL428496
HET
KWT
Wikipedia
Wortmannin
PDB Entries
1e7u / 3d5x / 3hhm

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.121 mg/mLALOGPS
logP2.31ALOGPS
logP1.44ChemAxon
logS-3.6ALOGPS
pKa (Strongest Basic)-3.2ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area109.11 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity106.86 m3·mol-1ChemAxon
Polarizability42.98 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9855
Blood Brain Barrier+0.957
Caco-2 permeable+0.5179
P-glycoprotein substrateSubstrate0.8161
P-glycoprotein inhibitor IInhibitor0.9581
P-glycoprotein inhibitor IIInhibitor0.9541
Renal organic cation transporterNon-inhibitor0.6551
CYP450 2C9 substrateNon-substrate0.8704
CYP450 2D6 substrateNon-substrate0.8509
CYP450 3A4 substrateSubstrate0.7654
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.5766
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7681
Ames testNon AMES toxic0.8847
CarcinogenicityNon-carcinogens0.9526
BiodegradationNot ready biodegradable0.9236
Rat acute toxicity4.0908 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8355
hERG inhibition (predictor II)Non-inhibitor0.6581
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as oxasteroids and derivatives. These are steroid derivatives where a carbon atom of the steroid is replaced by an oxygen atom.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Steroids and steroid derivatives
Sub Class
Oxasteroids and derivatives
Direct Parent
Oxasteroids and derivatives
Alternative Parents
Naphthopyrans / Naphthofurans / Naphthalenes / Furopyrans / Furoic acid esters / Aryl ketones / Pyrans / Dicarboxylic acids and derivatives / Heteroaromatic compounds / Lactones
show 5 more
Substituents
2-oxasteroid / Naphthopyran / Naphthofuran / Naphthalene / Furoic acid ester / Furopyran / Furoic acid or derivatives / Aryl ketone / Dicarboxylic acid or derivatives / Pyran
show 16 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
cyclic ketone, organic heteropentacyclic compound, acetate ester, delta-lactone (CHEBI:52289)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Protein serine/threonine kinase activity
Specific Function
Phosphoinositide-3-kinase (PI3K) that phosphorylates PtdIns(4,5)P2 (Phosphatidylinositol 4,5-bisphosphate) to generate phosphatidylinositol 3,4,5-trisphosphate (PIP3). PIP3 plays a key role by recr...
Gene Name
PIK3CG
Uniprot ID
P48736
Uniprot Name
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform
Molecular Weight
126452.625 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Protein serine/threonine kinase activity
Specific Function
Serine/threonine-protein kinase that performs several important functions throughout M phase of the cell cycle, including the regulation of centrosome maturation and spindle assembly, the removal o...
Gene Name
PLK1
Uniprot ID
P53350
Uniprot Name
Serine/threonine-protein kinase PLK1
Molecular Weight
68254.03 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Transmembrane receptor protein tyrosine kinase adaptor activity
Specific Function
Binds to activated (phosphorylated) protein-Tyr kinases, through its SH2 domain, and acts as an adapter, mediating the association of the p110 catalytic unit to the plasma membrane. Necessary for t...
Gene Name
PIK3R1
Uniprot ID
P27986
Uniprot Name
Phosphatidylinositol 3-kinase regulatory subunit alpha
Molecular Weight
83597.675 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Protein serine/threonine kinase activity
Specific Function
Phosphoinositide-3-kinase (PI3K) that phosphorylates PtdIns (Phosphatidylinositol), PtdIns4P (Phosphatidylinositol 4-phosphate) and PtdIns(4,5)P2 (Phosphatidylinositol 4,5-bisphosphate) to generate...
Gene Name
PIK3CA
Uniprot ID
P42336
Uniprot Name
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform
Molecular Weight
124283.025 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]

Drug created on September 15, 2010 15:28 / Updated on July 02, 2018 18:55